DiaSorin S p A : Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution

DIASORIN: PUBLICATION OF THE LISTS OF CANDIDATES FOR THE APPOINTMENT OF THE BOARD OF DIRECTORS AND OF THE BOARD OF STATUTORY AUDITORS AND RELEVANT PROPOSALS FOR RESOLUTION

Saluggia, April 8, 2022 - With reference to the Shareholders' meeting called on April 29 2022 in a single calling, DiaSorin (FTSE MIB: DIA) announces that no. 1 list for the appointment of the Board of Directors under item no. 3 of the agenda of the Shareholders' meeting and no. 2 lists for the appointment of the Board of Statutory Auditors under item no. 4 on the agenda of the Shareholders' meeting have been filed, by the deadline required pursuant to law, as follows:

Appointment of the Board of Directors

List filed by IP Investimenti e Partecipazioni S.r.l. (shareholding equal to 43.957% of the share capital)

• 1) Michele Denegri

• 2) Giancarlo Boschetti

• 3) Stefano Altara

• 4) Carlo Rosa

• 5) Chen Menachem Even

• 6) Franco Moscetti

• 7) Diego Pistone

• 8) André Michel Ballester (Independent)

9)Roberta Somati (Independent)

• 10) Francesca Pasinelli (Independent)

• 11) Fiorella Altruda (Independent)

• 12) Monica Tardivo (Independent)

• 13) Tullia Todros (Independent)

• 14) Luca Melindo

• 15) Giovanna Pacchiana Parravicini (Independent)

Appointment of the Board of Statutory Auditors

List no. 1 filed by IP Investimenti e Partecipazioni S.r.l. (shareholding equal to 43.957% of the share capital)

Statutory Auditors

• 1) Ottavia Alfano

• 2) Matteo Michele Sutera

• 3) Fabrizio Mosca

Alternate Auditors

• 1) Romina Guglielmetti

• 2) Marco Sandoli

List no. 2 filed by institutional investors altogether representing 0.691% of the share capital

Statutory Auditors

1) Monica Mannino

Alternate Auditors 1) Cristian Tundo

In the documents, accompanying List no. 2 for the appointment of the Board of Statutory Auditors it is included the declaration of absence of control relationships and/or significant relationships, also pursuant to CONSOB communication no. DEM/9017893 of February 26, 2009, with shareholders who - based on the notification of major holdings pursuant to art. 120 TUF or the publication of shareholders' agreements pursuant to art. 122 TUF - hold, also jointly, a controlling or majority relative shareholding as envisaged by art. 147-ter, paragraph 3, TUF and 144-quinquies of the Issuers Regulation.

IP Investimenti e Partecipazioni S.r.l. has also filed, within the terms and according to the modalities set forth by the law, the proposals for resolution concerning the appointment of the members of the Board of Directors with reference to items no. 3.1, 3.2. and 3.4. on the agenda of the Shareholders' Meeting - in relation to the directors' number, duration of the office and compensation - as well as the proposal for resolution concerning the compensation of the Board of Statutory Auditors under item 4.3. on the agenda of the Shareholders' Meeting.

The documentation pursuant to the article 144-octies of the Issuers Regulation adopted with CONSOB Resolution no. 11971/1999 and the proposals for resolution filed by IP Investimenti and Partecipazioni S.r.l. are available to the public at the Company's registered office, on the Company's website (www.diasoringroup.com, section "Governance"/ "Shareholders meetings"/"2022") and on the authorized storage mechanism used by the Company available on the websitewww.emarketstorage.com.

For additional information, please contact:

Riccardo Fava	Emanuela Salvini
Corporate Vice President Communication & Investor Relations	Investor Relator
Tel: [phone]	Tel: [phone]
[e-mail]	[e-mail]
About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 43 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info atwww.diasoringroup.com